ARVINAS INC (ARVN)
US04335A1051 - Common Stock
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical...
ARVN December 2025 Options Begin Trading
Noteworthy Wednesday Option Activity: AMGN, ARVN, PFSI
Arvinas to Participate in Upcoming Investor Conferences
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib...
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
Arvinas to Participate in Upcoming Investor Conferences
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024
ARVN stock results show that Arvinas beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arvinas (NASDAQ:ARVN) just reported results for the second quarter of 2024.Arvi...
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical...
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
Biotech Arvinas Stock Earns 82 RS Rating
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.
ARVN Makes Bullish Cross Above Critical Moving Average
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas,...
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell...
Arvinas Becomes Oversold (ARVN)
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
Arvinas to Participate in Upcoming Investor Conferences
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...